FOR IMMEDIATE RELEASE
AI Medical receives CE Mark for its innovative neuroimaging AI software Jazz
AI Medical is proud to announce that its innovative intelligent automation software Jazz, has received the CE marking following the European Union Medical Device Regulation (MDR). This designation signifies that the product complies with the essential health and safety requirements set forth by the European Union (EU).
Jazz is a cutting-edge artificial intelligence (AI) platform that is designed to assist healthcare professionals in making accurate and timely medical diagnoses. The product supports radiologists in producing high-quality reports, by automating low-level tedious tasks, such as lesion annotation, anatomical lesion position detection, and lesion volume measurement. Jazz is especially helpful for complex follow-up assessment of chronic diseases with magnetic resonance imaging, such as multiple sclerosis and brain metastasis.
The CE marking is a mandatory requirement for all medical devices sold in the EU and is recognized throughout the region as a symbol of quality and safety. By receiving this designation, Jazz is now eligible for commercialization and distribution throughout the EU, expanding its reach and impact on healthcare quality.
"We are thrilled to receive the CE marking for Jazz, which is a testament to the hard work and dedication of our team, as well as the quality of our products" said CEO Christian Federau. "Our goal has always been to make a positive impact on the healthcare industry and help improve patient outcomes. With the CE marking, we are one step closer to achieving that goal and bringing our innovative AI technology to the global market."
Zurich, Switzerland
02/02/2023